UTRS - Minerva Surgical, Inc. Stock Price, Fair Value and News

0USD0Market Closed

UTRS Stock Price

View Fullscreen

UTRS RSI Chart

UTRS Valuation

EV/EBITDA

-0.83

UTRS Price/Sales (Trailing)

UTRS Profitability

EBT Margin

-64.61%

Return on Equity

-165.14%

Return on Assets

-45.96%

UTRS Fundamentals

UTRS Revenue

Revenue (TTM)

51.7M

Rev. Growth (Yr)

-4.95%

Rev. Growth (Qtr)

-10.65%

UTRS Earnings

Earnings (TTM)

-33.5M

Earnings Growth (Yr)

36.61%

Earnings Growth (Qtr)

17.28%

Breaking Down UTRS Revenue

Last 30 days

-100%

Last 90 days

-100%

Trailing 12 Months

-100%

How does UTRS drawdown profile look like?

UTRS Financial Health

Current Ratio

1.88

Debt/Equity

1.38

Debt/Cashflow

-1.39

UTRS Investor Care

Shares Dilution (1Y)

512.98%

Diluted EPS (TTM)

-8.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	51.9M	52.3M	51.7M	0
2022	51.2M	50.1M	50.1M	50.3M
2021	41.4M	44.9M	48.5M	52.1M
2020	0	0	0	37.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Minerva Surgical, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2023	new enterprise associates 13 lp	bought	5,000,000	0.2046	24,437,900	-
Jul 19, 2022	sung derrick	acquired	199,999	2.3	86,956	-
Jun 10, 2022	anderson jill	acquired	119,999	2.41	49,792	-
Jun 10, 2022	renzi david	acquired	119,999	2.41	49,792	-
Jun 10, 2022	behbahani ali	acquired	119,999	2.41	49,792	-
Jun 10, 2022	coste catherine	acquired	119,999	2.41	49,792	-
Jun 10, 2022	hunt niquette l.	acquired	119,999	2.41	49,792	-
Jun 10, 2022	jaffe ross a md	acquired	119,999	2.41	49,792	-
May 02, 2022	jung joel r	acquired	-	-	60,198	cfo
May 02, 2022	filloux dominique j.	acquired	-	-	60,198	coo

Which funds bought or sold UTRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-3,155	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-3,109	-	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-2,433	-	-%
Feb 14, 2024	NEA Management Company, LLC	sold off	-100	-5,664,900	-	-%
Feb 14, 2024	STATE STREET CORP	sold off	-100	-26,616	-	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	sold off	-100	-34,458	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-636	-	-%
Feb 13, 2024	XTX Topco Ltd	sold off	-100	-4,570	-	-%
Feb 13, 2024	Frank, Rimerman Advisors LLC	sold off	-100	-18,281	-	-%
Feb 09, 2024	HRT FINANCIAL LP	sold off	-100	-1,000	-	-%

Are Funds Buying or Selling UTRS?

Are funds buying UTRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own UTRS

No. of Funds

Unveiling Minerva Surgical, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 28, 2023	accelmed partners ii l.p.	68.8%	122,189,638	SC 13D/A
Jul 07, 2023	new enterprise associates 13 lp	-	0	SC 13D/A
Jul 06, 2023	accelmed partners ii l.p.	69.1%	122,189,638	SC 13D/A
May 10, 2023	awm investment company, inc.	1.2%	2,109,444	SC 13G/A
Feb 21, 2023	new enterprise associates 13 lp	19.5%	34,437,052	SC 13D/A
Feb 14, 2023	awm investment company, inc.	5.6%	1,668,572	SC 13G
Feb 10, 2023	cvf, llc	7.8%	2,259,685	SC 13G/A
Feb 09, 2023	accelmed partners ii l.p.	69.3%	122,189,638	SC 13D
Jan 24, 2023	new enterprise associates 13 lp	33.5%	9,999,125	SC 13D/A
Nov 03, 2022	novo holdings a/s	4.5%	1,322,473	SC 13G/A

Peers (Alternatives to Minerva Surgical, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.8B	40.3B	-5.00%	-5.05%	32.67	4.56	-2.84%	-3.08%
BDX	68.4B	19.7B	-3.90%	-6.73%	51.29	3.47	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.51%	-8.38%	46.8	5.52	5.72%	46.72%
BAX	18.6B	14.9B	-14.34%	-20.72%	7.02	1.25	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.17%	22.48%	31.57	2.79	6.16%	35.06%
HSIC	8.8B	12.3B	-5.50%	-14.07%	21.17	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-13.13%	-26.81%	-12.92	3.08	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.57%	-31.60%	-62.73	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.38%	28.89%	-216.43	8.91	30.82%	65.57%
PDCO	2.3B	6.6B	-1.94%	-3.23%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	1.24%	-9.09%	-2.08	0.44	7.73%	-1066.14%
ANIK	413.1M	166.7M	8.74%	7.69%	-5	2.48	6.67%	-456.34%
ANGO	248.3M	324.0M	-11.81%	-28.90%	-1.29	0.77	-3.19%	-337.41%
APYX	48.5M	52.3M	-5.33%	-58.72%	-2.59	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-24.57%	300.00%	-0.28	0.92	5.77%	8.23%

Minerva Surgical, Inc. News

Latest updates

Minerva Surgical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	-10.6%	11,965	13,391	12,533	13,804	12,588	12,967	10,935	13,645	12,506	14,114	11,838	12,059	12,280
Gross Profit	-16.0%	6,218	7,402	7,015	7,371	6,813	7,645	5,413	7,825	7,133	8,732	6,833	-	6,555
Operating Expenses	-18.2%	12,314	15,060	17,325	12,563	17,321	12,544	15,713	14,478	13,273	20,295	11,623	-	9,726
S&GA Expenses	-28.3%	6,711	9,361	10,202	9,441	9,723	9,691	9,473	9,309	7,919	8,497	6,469	-	6,722
R&D Expenses	-4.3%	1,413	1,477	1,765	1,458	1,456	1,274	1,255	1,101	1,367	1,673	1,151	-	1,200
EBITDA Margin	12.6%	-0.39*	-0.45*	-0.39*	-0.40*	-0.06*	0.15*	0.04*	0.02*	0.02*	0.02*	0.02*	0.02*	-
Interest Expenses	3.8%	1,172	1,129	1,068	1,026	861	703	632	1,065	3,611	3,601	3,451	-	3,293
Income Taxes	-92.3%	3.00	39.00	-	11.00	-	-	-	9.00	-	-	-	-	-
Earnings Before Taxes	16.9%	-7,178	-8,642	-11,343	-6,234	-11,329	-5,613	-10,925	10,817	-3,225	-14,099	-14,948	-	-7,324
EBT Margin	10.0%	-0.65*	-0.72*	-0.67*	-0.68*	-0.34*	-0.18*	-0.34*	-0.41*	-0.38*	-0.41*	-0.44*	-0.49*	-
Net Income	17.3%	-7,181	-8,681	-11,343	-6,245	-11,329	-5,613	-10,925	10,808	-3,225	-14,099	-14,948	-6,371	-7,324
Net Income Margin	10.0%	-0.65*	-0.72*	-0.67*	-0.68*	-0.34*	-0.18*	-0.34*	-0.41*	-0.80*	-0.95*	-0.94*	-0.48*	-
Free Cashflow	46.9%	-5,112	-9,621	-8,461	-15,592	-6,805	-5,536	-7,707	-10,769	-5,526	-3,346	-3,322	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-8.2%	73.00	79.00	85.00	69.00	84.00	94.00	101	115	81.00	92.00
Current Assets	-13.2%	40.00	46.00	54.00	36.00	49.00	57.00	61.00	75.00	40.00	45.00
Cash Equivalents	-29.2%	11.00	16.00	25.00	7.00	15.00	22.00	28.00	41.00	6.00	17.00
Inventory	1.7%	18.00	18.00	17.00	17.00	17.00	17.00	16.00	16.00	15.00	10.00
Net PPE	1.2%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	4.00	3.00
Liabilities	-0.4%	53.00	53.00	51.00	52.00	62.00	63.00	66.00	71.00	205	191
Current Liabilities	17.6%	21.00	18.00	17.00	14.00	23.00	24.00	26.00	23.00	66.00	33.00
Long Term Debt	-10.3%	28.00	31.00	34.00	37.00	39.00	39.00	39.00	39.00	18.00	29.00
LT Debt, Current	38.8%	12.00	8.00	5.00	2.00	-	-	-	0.00	13.00	2.00
LT Debt, Non Current	-10.3%	28.00	31.00	34.00	37.00	39.00	39.00	39.00	39.00	18.00	29.00
Shareholder's Equity	-23.8%	20.00	27.00	34.00	17.00	22.00	31.00	35.00	44.00	-	-
Retained Earnings	-2.4%	-310	-303	-294	-283	-277	-266	-260	-249	-260	-228
Additional Paid-In Capital	0.3%	331	330	329	301	299	297	295	294	13.00	6.00
Shares Outstanding	0.0%	9.00	9.00	9.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	47.0%	-5,095	-9,608	-8,386	-15,644	-6,803	-5,495	-7,625	-11,073	-5,119	-3,266	-2,921	-	-
Cashflow From Investing	-30.8%	-17.00	-13.00	-75.00	52.00	-2.00	-41.00	-82.00	304	-407	-80.00	-401	-	-
Cashflow From Financing	-100.0%	-	79.00	26,774	2.00	13.00	18.00	-4,997	45,249	37.00	40.00	886	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

UTRS Income Statement

2023-09-30

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Condensed Statements of Operations - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenues	$ 11,965	$ 12,588	$ 37,889	$ 36,490
Cost of goods sold	5,747	5,775	17,254	16,619
Gross profit	6,218	6,813	20,635	19,871
Operating expenses
Sales and marketing	6,711	9,723	26,274	28,887
General and administrative	4,190	6,142	13,770	12,706
Research and development	1,413	1,456	4,655	3,985
Total operating expenses	12,314	17,321	44,699	45,578
Loss from operations	(6,096)	(10,508)	(24,064)	(25,707)
Interest income	92	42	277	70
Interest expense	(1,172)	(861)	(3,369)	(2,196)
Other expense, net	(2)	(2)	(7)	(34)
Net loss before income taxes	(7,178)	(11,329)	(27,163)	(27,867)
Income tax expense	(3)		(42)
Net Loss	$ (7,181)	$ (11,329)	$ (27,205)	$ (27,867)
Net loss per share attributable to common stockholders, basic	$ (0.81)	$ (7.92)	$ (3.49)	$ (19.48)
Net loss per share attributable to common stockholders, diluted	$ (0.81)	$ (7.92)	$ (3.49)	$ (19.48)
Weighted-average common shares used in computing net loss per share, basic	8,872,998	1,430,056	7,805,772	1,430,272
Weighted-average common shares used in computing net loss per share, diluted	8,872,998	1,430,056	7,805,772	1,430,272

UTRS Balance Sheet

2023-09-30

Condensed Balance Sheets - USD ($)
$ in Thousands

Sep. 30, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 11,125

$ 6,942

Restricted cash, current

604

Accounts receivable, net

7,569

7,244

Inventory

18,183

16,850

Prepaid expenses and other current assets

3,045

4,479

Total current assets

40,002

36,119

Restricted cash, net of current portion

265

Intangible asset, net

22,326

26,778

Property and equipment, net

5,427

5,042

Operating lease right-of-use asset

3,996

270

Other non-current assets

769

426

Total assets

72,785

68,900

Current liabilities:

Accounts payable

3,036

2,804

Accrued compensation

3,577

3,701

Accrued liabilities

2,366

5,524

Current portion of operating lease liability

623

355

Current portion of long-term debt

11,649

1,894

Total current liabilities

21,251

14,278

Long-term debt

27,885

37,441

Operating lease liability, net of current portion

3,394

Total liabilities

52,530

51,719

Commitments and contingencies (Note 8)

Stockholders’ deficit:

Preferred stock, $0.001 par value, 15,000,000 and 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively

Common stock, $0.001 par value, 300,000,000 and 100,000,000 shares authorized, 8,878,582 shares and 1,490,761 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively.

^[1]

Additional paid-in capital

330,953

300,837

Accumulated other comprehensive income

Accumulated deficit

(310,718)

(283,668)

Total stockholders' equity

20,255

17,181

Total liabilities and stockholders equity

$ 72,785

$ 68,900

[1]	Reduction of $28 thousand in common stock on December 31, 2022 represents the change in issued shares as a result of the 1-for-20 reverse stock split with the offsetting change recorded in addition paid-in capital.

About Minerva Surgical, Inc.

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

CEO	Mr. Todd Usen
WEBSITE	https://minervasurgical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	174

Minerva Surgical, Inc. Frequently Asked Questions

What is the ticker symbol for Minerva Surgical, Inc.? What does UTRS stand for in stocks?

UTRS is the stock ticker symbol of Minerva Surgical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Minerva Surgical, Inc. (UTRS)?

As of Fri May 03 2024, market cap of Minerva Surgical, Inc. is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTRS stock?

You can check UTRS's fair value in chart for subscribers.

What is the fair value of UTRS stock?

You can check UTRS's fair value in chart for subscribers. The fair value of Minerva Surgical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Minerva Surgical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Minerva Surgical, Inc. a good stock to buy?

The fair value guage provides a quick view whether UTRS is over valued or under valued. Whether Minerva Surgical, Inc. is cheap or expensive depends on the assumptions which impact Minerva Surgical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTRS.

What is Minerva Surgical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, UTRS's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTRS PE ratio will change depending on the future growth rate expectations of investors.